Study of AFP464 +/- Faslodex in ER + Breast Cancer

Stopped early · Phase 2

Conditions studied: Breast Neoplasm

In brief

AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.

Key facts

Study ID

NCT01233947

Run by

Tigris Pharmaceuticals

People needed

7

Starts

2011-05-01

Expected to finish

2012-08-01

Last updated by the study team

2012-01-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• proven breast cancer, ER+ status; progression on an aromatase inhibitor; measurable disease or evaluable disease with serum CA27.29>=50 U/mL; adequate bone marrow, liver and renal function; DLco grade 0 or 1.

You may not qualify if…

• HER2 positive, thoracic radiotherapy or symptomatic pulmonary disease, brain metastases,

Where it is running

• Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.